Table 5 Different approaches to therapy escalation
relapse | MRI | progression (EDSS) | remarks | |
|---|---|---|---|---|
Rio score (21) | ≥ 1 | ≥ 3 new T2 lesions | ≥ 1 point | 〈risk if the Rio score ≥ 2 points |
MAGNIMS score (22) | ≥ 1 | ≥ 3 new T2 lesions | - | 〈risk if the MAGNIMS score ≥ 2 points |
NEDA 3 | ≥ 1 | ≥ 1 new T2 lesions | ≥ 1 point | better for positive predictive value |
EAN/ECTRIMS g. 4 | ≥ 1 | 1 or 2 new T2 lesions | if ↑ (not defined) | combination of clinical and MRI parameters |
AAN guideline 5 | ≥ 1 | ≥ 2 new T2 lesions | if ↑ (not defined) | tolerability and adherence |
Canadian recommendation 6 | ≥ 1 major ≥ 2 minor | ≥ 3 new T2 lesions | > 1 point | close monitoring if there is any sign of disease activity |
German recommendation 7 | ≥ 1 | ≥ 2–3 new T2 lesions | 0.5-1 point | in line with NEDA concept |
Croatian recommendation 8 | ≥ 1 | ≥ 3 new T2 lesions | - | combination of clinical and MRI parameters |